28 November 2018 Paris
Affordable access to many drugs is made difficult by high prices. At the same time, serious questions are being asked about the degree of innovation and value offered by increasingly costly treatments.
A number of competition enforcement actions against excessive pricing have recently taken place in the pharmaceutical sector, despite competition authorities usually being reluctant to intervene directly against high prices. In common with other instances of application of competition law in the pharmaceutical sector, these cases require a deep understanding of market dynamics and sectoral regulation, and of the various regulatory responses that may be deployed to address high prices.
In November 2018, the OECD held a discussion on excessive prices at the intersection between competition law and regulated sectors such as pharma.
All related materials for the discussion are available on this page.
View the full list of OECD best practice roundtables on competition policy
John DAVIES Bio
Margherita COLANGELO Bio
Margaret KYLE Bio
OECD background note • Note de référence de l'OCDE
Executive Summary with key findings • Synthèse des points clés de la discussion
Detailed Summary of the discussion • Compte rendu detaillé de la discussion
OECD Competition Youtube channel
2019 Session on excessive prices in pharmaceutical markets, OECD Competition Open Day
RELATED DOCUMENTS AND LINKS
Excessive prices in pharmaceutical markets, 2019 OECD Competition Open Day
Competition issues in the distribution of pharmaceuticals, 2014
Competition and Generic Pharmaceuticals, 2014
Excessive Prices, 2011
Generic Pharmaceuticals, 2009
Monopsony and Buyer Power, 2008
Competition and Regulation Issues in the Pharmaceutical Industry, 2000
Abuse of dominance and monopolisation
Liberalisation and competition intervention in regulated sectors
OECD best practice roundtables on competition